Welcome to the UPCET website, your academic partner to manage clinical trials

The Pharmacology and Toxicology Unit – CHU (teaching hospital) in Lyon consists of 5 operational units:

Posted in Uncategorized | Leave a comment

Collaboration with EMET team

The EMET (Evaluation and Modelling with the Therapeutic Effects Group) team, which is part of the Biometry and Evolutionary Biology laboratory (LBBE), works closely with our platform, particularly to optimise the development of therapeutics.

Sample size calculation has become a must in any clinical research project. It is a concrete illustration of how modelling, often being very simple, helps in optimising experimental designs by involving the right number of patients. The considered parameters include statistical risks of false positive or false negative results, the expected size of treatment effect and the variability outcomes on which the effect will be measured.

PK/PD (Pharmacokinetic/Pharmacodynamic) modelling is deeply rooted in pharmacology culture. It has been enriched by the addition of population-based approaches enabling a better grasp of the interindividual variability.

The EMET team is adding disease modelling to this culture, in accordance with phenomenological and mechanistic approaches, so that therapeutics can be modelled in its entirety (drug-disease relationships). The integration of the whole therapeutic model in multiple individual profiles, thereby generating hypothetical or realistic virtual populations, enables the simulation of clinical trials, just like in the CRESIM project. The specific ambition CRESIM has is to help in the choice of experimental design.

The coupling of therapeutic model with realistic virtual population is used to simulate the public health impact (link to article by Ivanny),  validate new therapeutic strategies (doi: 10.1371/journal.pone.0017508, doi: 10.1371/journal.pone.0140793) or explore new avenues/therapeutic targets (http://www.novadiscovery.com/).

Posted in Uncategorized | Leave a comment

CRESIM (Child-Rare-Euro-Simulation)

Use of clinical trial simulation for the optimisation of study designs in rare diseases CRESIM

[EMET Team: N.Bleyzac, C. Cornu, B. Kassaï, P. Nony, P. Reix]

The CRESim project (headed by P. Nony) is a PrioMedChild European project. Its objective is to optimise the study design selection of a randomised controlled trial (RCT) for rare diseases and orphan treatments (Cornu et al.2013).The CRESim project develops a platform performing trial modelling and simulation («cloud computing technology ») (See figure below), initially based on three pathological situations: Dravet Syndrome (rare form of epilepsy), T-cell lymphoblastic lymphoma in children and cystic fibrosis. The common approach is an integrative modelling, using the development and connection between the pathophysiological model of the disease, the pharmacotherapeutic model of the study treatment (i.e. relationship between pharmacokinetics and pharmacodynamics [Ogungbenro et al.2014])) and the clinical trial model with a specific trial design.

The mathematical formalism uses systems of ordinary differential equations (ODE) and reaction-diffusion system of equations (EDP) for most of the models concerned. The project’s central ambitions are divided into the following four main areas:

1) Science: the multidisciplinary integrative modelling (clinicians, pathophysiologists, pharmacologists, therapists, mathematicians, modellers, numerical analysts and computer specialists) meets the very specific needs in the field of rare diseases, with the in silico development and validation of new surrogate endpoints, of  “theranostic” approaches, allowing for the implementation of a personalised medicine.

2) Education: with a dissemination of findings to scientific communities, to the pharmaceutical and biotherapeutics industry, and to patient associations.

3) Regulation: The results of the CRESIM project should modify the position of the modelling/simulation in recommendations on developing medicines.

4) Public Health: the expected acceleration of the orphan drug development process and the improvement of the evidence level available on the risk-benefit ratio associated with their use, should transform the world of rare diseases and their therapy.

Cresim (1)  cresim2-300x219



Posted in Uncategorized | Leave a comment